Early Lung Cancer Detection
Cizzle Biotechnology (LSE: CIZ) is developing a simple blood test to detect lung cancer early,
when treatment is most effective.
Shareholder Information
Cizzle Biotechnology Holdings plc‘s shares are traded on Main Market of the London Stock Exchange.
Significant Shareholders
As at 08 April 2025, as far as the Directors are aware, the following shareholders have a significant interest in the issued share capital of the Company.
| Name | Number of Ordinary Shares | % of Issued Share Capital |
|---|---|---|
| Hargreaves Lansdown (Nominees) Limited | 44,809,977 | 11.30 |
| Yorkshire Cancer Research | 32,382,330 | 8.17 |
| Interactive Investor Services Nominees Limited | 31,333,630 | 7.90 |
| Hargreaves Lansdown (Nominees) Limited | 29,870,003 | 7.54 |
| Hargreaves Landsown (Nominees) Limited | 28,109,647 | 7.809 |
| Barclays Direct Investing Nominees Limited | 20,322,951 | 5.13 |
| Interactive Investor Services Nominees Limited | 19,460,025 | 4.91 |
| HSDL Nominees Ltd | 17,226,581 | 4.35 |
| Professor Dawn Coverley* | 17,048,137 | 4.30 |
| HSBC Global Custody Nominee (UK) Limited | 14,718,227 | 3.71 |
* the shareholding of Professor Dawn Coverley includes shares held by Dawn’s husband, Dr Juston Ainscough.
